7 results
PCI in Acute MI with Cardiogenic Shock. #EBM #Cardiology #CULPRITSHOCK #PCI #VisualAbstract #NEJM
PCI in Acute MI ... #EBM #Cardiology ... #CULPRITSHOCK #PCI ... VisualAbstract #NEJM
Cumulative Incidence of Progression of MGUS, with Death Accounted for as a Competing Risk #EBM #Honc
Progression of MGUS ... Competing Risk #EBM ... #Honc #MGUS #Progression ... #IgG #MGUS #NEJM
IgM and Non-IgM - Risk and Type of Progression #EBM #Honc #MGUS #Progression #IgM #NonIgM #MultipleMyeloma
of Progression #EBM ... #Honc #MGUS #Progression ... MultipleMyeloma #NEJM
Bivalirudin versus Heparin Monotherapy in Myocardial Infarction (VALIDATE-SWEDEHEART) #EBM #Cardiology #VALIDATE #SWEDEHEART #Bivalirudin #Heparin #PCI #VisualAbstract
VALIDATE-SWEDEHEART) #EBM ... #Cardiology #VALIDATE ... Bivalirudin #Heparin #PCI ... VisualAbstract #NEJM
PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock - Event Rates of the
PCI Strategies in ... #EBM #Cardiology ... #CULPRITSHOCK #PCI ... #cardiogenic #NEJM
Event Rates of the Primary End Point and Its Components at 30 Days #EBM #Cardiology #CULPRIT-SHOCK
Components at 30 Days #EBM ... #Cardiology #CULPRIT-SHOCK ... #CULPRITSHOCK #PCI ... #cardiogenic #NEJM
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation (RE-DUAL PCI trial) - Shown is
Dabigatran after PCI ... Fibrillation (RE-DUAL PCI ... warfarin (Panel A) #EBM ... #Cardiology #IM ... AtrialFibrillation #NEJM